Movatterモバイル変換

[0]ホーム
URL:

US20120039900A1 - Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders - Google Patents

Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disordersDownload PDF

Info

Publication number
US20120039900A1
US20120039900A1US13/282,850US201113282850AUS2012039900A1US 20120039900 A1US20120039900 A1US 20120039900A1US 201113282850 AUS201113282850 AUS 201113282850AUS 2012039900 A1US2012039900 A1US 2012039900A1
Authority
US
United States
Prior art keywords
genbank accession
subject
biomarkers
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/282,850
Inventor
Bruno Stuhlmüller
Gerd-Reudiger Burmester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott LaboratoriesfiledCriticalAbbott Laboratories
Priority to US13/282,850priorityCriticalpatent/US20120039900A1/en
Publication of US20120039900A1publicationCriticalpatent/US20120039900A1/en
Assigned to ABBVIE INC.reassignmentABBVIE INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: ABBOTT LABORATORIES
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The invention provides methods for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis. The methods involve assaying for expression of one or more biomarkers in the subject that are predictive of responsiveness to TNFα inhibitors. A preferred biomarker of the invention is CD11c. The methods can further comprise selecting a treatment regimen with a TNFα inhibitor in an autoimmune disorder subject based upon expression of the biomarker(s) in the subject. The methods can further comprise administering a TNFα inhibitor to the subject according to the selected treatment regimen. Kits that include means for measuring expression of one or more biomarkers that are predictive of responsiveness to TNFα inhibitors for an autoimmune disorder are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting an autoimmune disorder subject for treatment with a TNFα inhibitor are also provided.

Description

Claims (22)

What is claimed is:
1. A method for predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, the method comprising: (i) assaying the subject for expression of one or more biomarkers predictive of responsiveness to a TNFα inhibitor in an autoimmune disorder, and (ii) predicting responsiveness of the subject to the TNFα inhibitor based on expression of the one or more biomarkers in the subject, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-10, 12-28, 30-43, 45-61, 63, 64, 66-73, and 75-82,
wherein decreased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-5, 8, 9, 12-14, 18, 20, 21, 23, 25, 26, 28, 30, 32, 33, 40-42, 48, 50, 52, 53, 56, 58, 60, 63, 66-69, 71-73, 76-78, 80 and 81 is predictive of responsiveness of the subject to a TNFα inhibitor; and/or
wherein increased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 7, 10, 15-17, 19, 22, 24, 27, 31, 34-39, 43, 45-47, 49, 51, 54, 55, 57, 59, 61, 64, 70, 75, 79 and 82 is predictive of responsive of the subject to a TNFα inhibitor.
2. A method for predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, the method comprising:
(i) assaying the subject for expression of one or more biomarkers predictive of responsiveness to a TNFα inhibitor in an autoimmune disorder, and
(ii) predicting responsiveness of the subject to the TNFα inhibitor based on expression of the one or more biomarkers in the subject, wherein the one or more biomarkers is selected from the group consisting of Aquaporin 3 (Genbank Accession No. NM—004925); Similar to ribosomal protein S24, clone MGC:8595 (Genbank Accession No. NM—033022); Transmembrane emp24 domain trafficking protein 2 (Genbank Accession No. NM—006815); Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (Genbank Accession No. NM—000454); Calmodulin 1 (phosphorylase kinase, delta) (Genbank Accession No. NM—006888); Guanine nucleotide binding protein (G protein), beta polypeptide 1 (Genbank Accession No. NM—002074); Prothymosin, alpha (gene sequence 28) (Genbank Accession No. NM—002823);Homo sapiensisocitrate dehydrogenase 1 (NADP+) soluble (IDH1) (Genbank Accession No. NM—005896); Tumor protein D52 (Genbank Accession Nos. NM—001025252, NM—001025253, NM—005079); Early growth response 1 (Genbank Accession No. NM—001964); Cytochrome c oxidase subunit VIIb (Genbank Accession No. NM—001866); CUG triplet repeat, RNA binding protein 2 (Genbank Accession No. NM—001025077, NM—001025076, NM—006561); Ubiquinol-cytochrome c reductase hinge protein (Genbank Accession No. NM—006004);Homo sapiensleptin receptor gene-related protein (HS0BRGRP) (Genbank Accession No. NM—017526); Wiskott-Aldrich syndrome protein interacting protein (Genbank Accession Nos. NM—001077269, NM—003387); CD97 antigen (Genbank Accession Nos. NM—001025160, NM—001784, NM—078481); Glutamate-cysteine ligase, catalytic subunit (Genbank Accession No. NM—001498); Crystallin, zeta (quinone reductase) (Genbank Accession No. NM—001889); Rap guanine nucleotide exchange factor (GEF) 2 (Genbank Accession No. NM—014247); Ataxin 1 (Genbank Accession No. NM—000332); Adaptor-related protein complex 1, sigma 2 subunit (Genbank Accession No. NM—003916); Ectonucleotide pyrophosphatase/phosphodiesterase 4 (Genbank Accession No. NM—014936); Desmocollin 2 (Genbank Accession Nos. NM—024422, NM—004949); MAL, T-cell differentiation protein (Genbank Accession Nos. NM—002371, NM—022438, NM—022439, NM—022440); Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (Genbank Accession No. NM—005476); Chemokine (C—C motif) ligand 3 (Genbank Accession Nos. NM—001001437, NM—021006); Carboxypeptidase A3 (Genbank Accession No. NM—001870); NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7 kDa (Genbank Accession No. NM—004545); Interleukin 8 receptor, beta (Genbank Accession No. NM—001557); Platelet factor 4 variant 1 (Genbank Accession No. NM—002620); Poly(A) binding protein interacting protein 1 (Genbank Accession No. NM—006451); ATP-binding cassette, sub-family C (CFTR/MRP), member 3 (Genbank Accession No. NM—003786); Actinin, alpha 1 (Genbank Accession No. NM—001102); NAD kinase (Genbank Accession No. NM—023018); Platelet/endothelial cell adhesion molecule (CD31 antigen) (Genbank Accession No. NM—000442); Esterase D/formylglutathione hydrolase (Genbank Accession No. NM—001984); Chromosome 20 open reading frame 111 (Genbank Accession No. NM—016470); Sterol-C4-methyl oxidase-like (Genbank Accession Nos. NM—001017369, NM—006745); PIM-1 oncogene (Genbank Accession No. NM—002648); GATA binding protein 2 (Genbank Accession No. NM—032638); Cathepsin Z (Genbank Accession No. NM—001336); Lectin, galactoside-binding, soluble, 8 (galectin 8) (Genbank Accession Nos. NM—006499, NM—201545); CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) (Genbank Accession Nos. NM—006889, NM—175862); Interleukin 8 (Genbank Accession No. NM—000584); Fc fragment of IgE, high affinity I, receptor for alpha polypeptide (Genbank Accession No. NM—002001); Actin, gamma 1 (Genbank Accession No. NM—001614); KIAA0746 protein (Genbank Accession No. NM—015187); Glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (Genbank Accession No. NM—002076); Transcription factor 4 (Genbank Accession Nos. BF592782, CR612521); Major histocompatibility complex, class II, DQ alpha 1 (Genbank Accession Nos. NM—002122, NM—020056); Cell division cycle 2-like 6 (CDK8-like) (Genbank Accession No. NM—015076); Major histocompatibility complex, class II, DQ beta 1 (Genbank Accession No. XM—942240); Phospholipase C-like 2 (Genbank Accession No. NM—015184); Coagulation factor II (thrombin) receptor-like 1 (Genbank Accession No. NM—005242); TM2 domain containing 1 (Genbank Accession No. NM—032027); Splicing factor 3b, subunit 1, 155 kDa (Genbank Accession No. NM—012433); SUB1 homolog (S. cerevisiae) (Genbank Accession No. NM—006713); MRNA, cDNA DKFZp564O0862 (Genbank Accession No. AI278204); Cytochrome b-5 (Genbank Accession Nos. NM—001914, NM—148923); Cold autoinflammatory syndrome 1 (Genbank Accession No. NM—183395); Ribosomal protein S26, 40S ribosomal protein (Genbank Accession No. XM—941927); CCR4-NOT transcription complex, subunit 6 (Genbank Accession No. NM—015455); Ubiquinol-cytochrome c reductase complex (7.2 kD) (Genbank Accession Nos. NM—013387, NM—001003684); Hepatocellular carcinoma-associated antigen 112 (Genbank Accession No. NM—018487); Kruppel-like factor 11 (Genbank Accession No. XM—001129527); GGA binding partner (Genbank Accession No. NM—018318); Cornichon homolog 4 (Drosophila) (Genbank Accession No. NM—014184); Hypothetical protein FLJ21616 (Genbank Accession No. NM—024567); Nuclear prelamin A recognition factor (Genbank Accession Nos. NM—012336, NM—001038618); Erythroblast membrane-associated protein (Genbank Accession Nos. NM—018538, NM—001017922); LR8 protein (Genbank Accession No. NM—014020); Likely ortholog of mouse limb-bud and heart gene (LBH) (Genbank Accession No. NM—030915); Calmin (calponin-like, transmembrane) (Genbank Accession No. NM—024734); Chromosome 14 open reading frame 156 (Genbank Accession No. NM—031210); Guanine nucleotide binding protein (G protein) alpha 12 (Genbank Accession No. NM—007353); and SRY (sex determining region Y)-box 18 (Genbank Accession No. NR—003287).
3. A method for predicting responsiveness to a TNFα inhibitor, which TNFα inhibitor is adalimumab, in a subject having an autoimmune disorder, the method comprising:
(i) assaying the subject for expression of one or more biomarkers predictive of responsiveness to adalimumab in an autoimmune disorder, and
(ii) predicting responsiveness of the subject to adalimumab based on expression of the one or more biomarkers in the subject,
wherein decreased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-5, 8, 9, 12-14, 18, 20, 21, 23, 25, 26, 28, 30, 32, 33, 40-42, 48, 50, 52, 53, 56, 58, 60, 63, 66-69, 71-73, 76-78, 80 and 81 is predictive of responsiveness of the subject to a TNFα inhibitor; and/or
wherein increased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 7, 10, 15-17, 19, 22, 24, 27, 31, 34-39, 43, 45-47, 49, 51, 54, 55, 57, 59, 61, 64, 70, 75, 79 and 82 is predictive of responsive of the subject to a TNFα inhibitor.
4. The method of any ofclaims 1-3, wherein a sample from the subject is assayed for expression of mRNA encoding the one or more biomarkers.
5. The method of any ofclaims 1-3, wherein a sample from the subject is assayed for protein expression of the one or more biomarkers.
6. The method of any ofclaims 1-3, which further comprises selecting a treatment regimen with the TNFα inhibitor based upon expression of the one or more biomarkers in the subject.
7. The method ofclaim 6, which further comprises administering the TNFα inhibitor to the subject according to the treatment regimen such that the autoimmune disorder is inhibited in the subject.
8. The method of any ofclaims 1-3, wherein the TNFα inhibitor is an anti-tumor necrosis factor-alpha (TNFα) antibody, or antigen-binding portion thereof.
9. The method ofclaim 8, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is a human antibody, a humanized antibody, a chimeric antibody or a multivalent antibody.
10. The method ofclaim 8, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is adalimumab.
11. The method ofclaim 9, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is selected from the group consisting of
i) an isolated human antibody that dissociates from human TNFα with a Kd of 1×10−8M or less and a Koff rate constant of 1×10−3s−1or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7M or less;
ii) an isolated human antibody with the following characteristics:
a) dissociates from human TNFα with a Koff rate constant of 1×10-3 s-1 or less, as determined by surface plasmon resonance;
b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 305, or modified from SEQ ID NO: 305 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9;
c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 306, or modified from SEQ ID NO: 306 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12; and
iii) an isolated human antibody with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 303 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 304.
12. The method ofclaim 1, wherein the TNFα inhibitor is etanercept.
13. The method of any one ofclaims 1-3, wherein the subject is a human.
14. The method of any one ofclaims 1-3, wherein the autoimmune disorder is rheumatoid arthritis.
15. A kit for predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, the kit comprising:
a) means for isolating monocytes;
b) means for measuring expression in the subject of one or more biomarkers predictive of responsiveness to a TNFα inhibitor in an autoimmune disorder;
c) means for measuring expression of at least one housekeeping gene; and
d) instructions for use of the kit to predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, wherein decreased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-5, 8, 9, 11-14, 18, 20, 21, 23, 25, 26, 28-30, 32, 33, 40-42, 48, 50, 52, 53, 56, 58, 60, 63, 65-69, 71-74, 76-78, 80 and 81 is predictive of responsiveness of the subject to a TNFα inhibitor and/or wherein increased expression of the one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 7, 10, 15-17, 19, 22, 24, 27, 31, 34-39, 43, 44-47, 49, 51, 54, 55, 57, 59, 61, 62, 64, 70, 75, 79 and 82 is predictive of responsive of the subject to a TNFα inhibitor.
16. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 83-133, thereby monitoring the autoimmune disorder in the subject.
17. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 134-177, 110, 112, 118, 123 and 131, thereby monitoring the autoimmune disorder in the subject.
18. A method of monitoring an autoimmune disorder in a subject having an autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 178-292, 91 and 97, thereby monitoring the autoimmune disorder in the subject.
19. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 87, 97, 101, 293, 92, 272, 93, 107, 108, 121 and 123, and wherein the subject is monitored prior to treatment with a TNFα inhibitor, thereby monitoring the autoimmune disorder in the subject.
20. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 290, 209, 98, 112, 116, 121, 130, 155, 92, 289, 216 and 131, and wherein the subject is monitored after treatment with a TNFα inhibitor, thereby monitoring the autoimmune disorder in the subject.
21. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 97, 102, 29, 294, 295, 91, 131, 290, 100, 134, 296, 297, 298, 299, 136, 174 and 300, thereby monitoring the autoimmune disorder in the subject.
22. A method of selecting an autoimmune disorder subject for a treatment with a TNFα inhibitor, the method comprising:
(i) identifying, in a database comprising a plurality of autoimmune disorder subjects, a subject whose database entry is associated with a biomarker expression pattern that is predictive of responsiveness to treatment with a TNFα inhibitor, and
(ii) selecting the subject for treatment with a TNFα inhibitor, wherein the biomarker expression pattern reports expression in the subject of one or more biomarkers encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-82.
US13/282,8502007-05-312011-10-27Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disordersAbandonedUS20120039900A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US13/282,850US20120039900A1 (en)2007-05-312011-10-27Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US93288807P2007-05-312007-05-31
US12/130,373US8092998B2 (en)2007-05-312008-05-30Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
US13/282,850US20120039900A1 (en)2007-05-312011-10-27Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US12/130,373ContinuationUS8092998B2 (en)2007-05-312008-05-30Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders

Publications (1)

Publication NumberPublication Date
US20120039900A1true US20120039900A1 (en)2012-02-16

Family

ID=40094338

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US12/130,373Active2028-06-07US8092998B2 (en)2007-05-312008-05-30Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
US13/282,850AbandonedUS20120039900A1 (en)2007-05-312011-10-27Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
US12/130,373Active2028-06-07US8092998B2 (en)2007-05-312008-05-30Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders

Country Status (3)

CountryLink
US (2)US8092998B2 (en)
EP (3)EP2679995A1 (en)
WO (1)WO2008150491A2 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20060009385A1 (en)*2004-04-092006-01-12Abbott Biotechnology Ltd.Multiple-variable dose regimen for treating TNFalpha-related disorders
US20080166348A1 (en)*2006-04-102008-07-10Hartmut KupperUses and compositions for treatment of rheumatoid arthritis
US20090110679A1 (en)*2007-07-132009-04-30Luk-Chiu LiMethods and compositions for pulmonary administration of a TNFa inhibitor
US20090148513A1 (en)*2007-08-082009-06-11Wolfgang FraunhoferCompositions and methods for crystallizing antibodies
US20100021451A1 (en)*2006-06-082010-01-28Wong Robert LUses and compositions for treatment of ankylosing spondylitis
US20100278822A1 (en)*2009-05-042010-11-04Abbott Biotechnology, Ltd.Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2013138909A1 (en)*2012-03-192013-09-26University Of ManitobaDetection and modulation of rheumatoid arthritis
US8747854B2 (en)2010-06-032014-06-10Abbvie Biotechnology Ltd.Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
US8772458B2 (en)2006-10-272014-07-08Abbvie Biotechnology LtdCrystalline anti-hTNFalpha antibodies
US8883156B2 (en)2006-04-052014-11-11Abbvie Biotechnology Ltd.Purified antibody composition
US8906373B2 (en)2002-07-192014-12-09Abbvie Biotechnology Ltd.Use of TNF-alpha inhibitor for treatment of psoriasis
US8921526B2 (en)2013-03-142014-12-30Abbvie, Inc.Mutated anti-TNFα antibodies and methods of their use
US8946395B1 (en)2013-10-182015-02-03Abbvie Inc.Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en)2013-10-182015-04-28Abbvie, Inc.Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9062106B2 (en)2011-04-272015-06-23Abbvie Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en)2013-03-142015-06-30Abbvie, Inc.Protein purification using displacement chromatography
US9085618B2 (en)2013-10-182015-07-21Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9085619B2 (en)2007-11-302015-07-21Abbvie Biotechnology Ltd.Anti-TNF antibody formulations
US9086418B2 (en)2005-11-012015-07-21Abbvie Biotechnology Ltd.Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US9150645B2 (en)2012-04-202015-10-06Abbvie, Inc.Cell culture methods to reduce acidic species
US9181337B2 (en)2013-10-182015-11-10Abbvie, Inc.Modulated lysine variant species compositions and methods for producing and using the same
US9181572B2 (en)2012-04-202015-11-10Abbvie, Inc.Methods to modulate lysine variant distribution
US9193787B2 (en)2012-04-202015-11-24Abbvie Inc.Human antibodies that bind human TNF-alpha and methods of preparing the same
US9206390B2 (en)2012-09-022015-12-08Abbvie, Inc.Methods to control protein heterogeneity
US9234033B2 (en)2012-09-022016-01-12Abbvie, Inc.Methods to control protein heterogeneity
US9249182B2 (en)2012-05-242016-02-02Abbvie, Inc.Purification of antibodies using hydrophobic interaction chromatography
US9279015B2 (en)2006-04-102016-03-08Robert L. WongMethods for treatment of ankylosing spondylitis using TNF alpha antibodies
US9387246B2 (en)2013-09-032016-07-12L. Douglas GrahamTreatment methods for rheumatoid arthritis
US9499614B2 (en)2013-03-142016-11-22Abbvie Inc.Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9550826B2 (en)2013-11-152017-01-24Abbvie Inc.Glycoengineered binding protein compositions
US9598667B2 (en)2013-10-042017-03-21Abbvie Inc.Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9605064B2 (en)2006-04-102017-03-28Abbvie Biotechnology LtdMethods and compositions for treatment of skin disorders
WO2017132557A3 (en)*2016-01-292017-09-14BluePrint Bio, Inc.Prediction of therapeutic response in inflammatory conditions
US10179811B2 (en)2015-04-102019-01-15Fresenius Kabi Deutschland GmbhMethods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody
WO2022051245A3 (en)*2020-09-012022-04-14Scipher Medicine CorporationMethods and systems for predicting response to anti-tnf therapies
US11783913B2 (en)2019-06-272023-10-10Scipher Medicine CorporationMethods of treating a subject suffering from rheumatoid arthritis with alternative to anti-TNF therapy based in part on a trained machine learning classifier
US11987620B2 (en)2018-03-162024-05-21Scipher Medicine CorporationMethods of treating a subject with an alternative to anti-TNF therapy

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6090382A (en)1996-02-092000-07-18Basf AktiengesellschaftHuman antibodies that bind human TNFα
CN103275221B (en)1996-02-092016-08-17艾伯维生物技术有限公司People's antibody in conjunction with human TNF alpha
US20040009172A1 (en)*2002-04-262004-01-15Steven FischkoffUse of anti-TNFalpha antibodies and another drug
US20090280065A1 (en)*2006-04-102009-11-12Willian Mary KUses and Compositions for Treatment of Psoriasis
PT1944322E (en)*2002-07-192015-07-01Abbvie Biotechnology LtdTreatment of tnf alpha related disorders
US20040033228A1 (en)2002-08-162004-02-19Hans-Juergen KrauseFormulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en)*2002-10-242014-02-28Abbvie Biotechnology LtdLow dose methods for treating disorders in which tnf? activity is detrimental
GB0414054D0 (en)2004-06-232004-07-28Owen Mumford LtdImprovements relating to automatic injection devices
WO2006041970A2 (en)*2004-10-082006-04-20Abbott Biotechnology Ltd.Treatment of respiratory syncytial virus (rsv) infection
US8874477B2 (en)2005-10-042014-10-28Steven Mark HoffbergMultifactorial optimization system and method
EP2007426A4 (en)2006-04-102010-06-16Abbott Biotech LtdUses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en)*2006-04-102008-05-22Medich John RUses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en)*2006-04-102009-12-24Pollack Paul FUses and compositions for treatment of CROHN'S disease
US20080131374A1 (en)*2006-04-192008-06-05Medich John RUses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en)*2006-06-082008-12-18Hoffman Rebecca SUses and compositions for treatment of psoriatic arthritis
KR101396797B1 (en)2006-06-302014-05-26애브비 바이오테크놀로지 리미티드Automatic injection device
US8999337B2 (en)2007-06-112015-04-07Abbvie Biotechnology Ltd.Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2217250A4 (en)2007-11-092011-01-05California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
CA2707483A1 (en)2007-11-302009-06-11Wolfgang FraunhoferProtein formulations and methods of making same
US20090271164A1 (en)*2008-01-032009-10-29Peng Joanna ZPredicting long-term efficacy of a compound in the treatment of psoriasis
RU2537139C2 (en)2008-01-152014-12-27Эбботт Гмбх Унд Ко.КгProtein powder compositions and methods for preparing them
ES2335381B1 (en)2008-09-242011-02-28Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron IN VITRO METHOD AND KIT FOR THE FORECAST OR PREDICTION OF THE RESPONSE PART OF PATIENTS WITH REUMATOID ARTHRITIS TO THE TREATMENT WITH BLOCKING AGENTS OF THE TNFALFA FACTOR.
PE20120835A1 (en)2009-04-162012-07-23Abbvie Biotherapeutics Inc ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES
JP2012524910A (en)*2009-04-232012-10-18カリフォルニア インスティチュート オブ テクノロジー Method and system for identifying immunomodulators
WO2010127146A1 (en)*2009-04-292010-11-04Abbott Biotechnology LtdAutomatic injection device
US9200324B2 (en)2009-10-152015-12-01Crescendo BioscienceBiomarkers and methods for measuring and monitoring inflammatory disease activity
EP2512558A4 (en)*2009-12-152014-08-13Abbvie Biotechnology Ltd IMPROVED TRIP PUSHER FOR AUTOMATIC INJECTION DEVICE
JP2013526845A (en)*2010-03-242013-06-27ティーシー・ランド・エクスプレッション Genes and combinations of genes that predict an initial response or non-response of a subject suffering from an inflammatory disease to a cytokine targeted drug (CyTD)
HUE040658T2 (en)2010-04-072019-03-28California Inst Of TechnVehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
MX344727B (en)2010-11-112017-01-05Abbvie Biotechnology LtdIMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS.
BR112013018905B1 (en)2011-01-242021-07-13Abbvie Biotechnology Ltd AUTOMATIC INJECTION DEVICES THAT HAVE OVERMOLDED HANDLE SURFACES.
US20150240304A1 (en)*2011-01-252015-08-27Alessandra CervinoGenes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
US9539281B2 (en)2011-07-122017-01-10The Brigham And Women's Hospital, Inc.Lipid-containing PSA compositions, methods of isolation and methods of use thereof
HU230680B1 (en)*2012-10-192017-08-28Egis Gyogyszergyar Nyilvanosan Muekoedoe ReszvenytarsasagDiagnostic method
CA2899449A1 (en)2013-03-142014-10-02Abbvie Inc.Low acidic species compositions and methods for producing the same using displacement chromatography
SG11201504260UA (en)2013-03-142015-10-29Abbvie IncLow acidic species compositions and methods for producing and using the same
WO2014182966A1 (en)2013-05-102014-11-13California Institute Of TechnologyProbiotic prevention and treatment of colon cancer
EP2813850A1 (en)*2013-06-102014-12-17INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for predicting rheumatoid arthritis treatment response
CA2926588C (en)2013-10-162020-07-21Oncobiologics, Inc.Buffer formulations for enhanced antibody stability
EP3126846A4 (en)2014-04-022017-08-30Crescendo BioscienceBiomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
JP2017523437A (en)2014-06-102017-08-17クレッシェンド バイオサイエンス インコーポレイテッド Biomarkers and methods for measuring and monitoring disease activity in axial spondyloarthritis
WO2016004197A1 (en)2014-07-032016-01-07Abbvie Inc.Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en)2014-07-092016-06-30Abbvie Inc.Methods for modulating the glycosylation profile of recombinant proteins using sugars
WO2016118707A1 (en)2015-01-212016-07-28Oncobiologics, Inc.Modulation of charge variants in a monoclonal antibody composition
WO2016201342A1 (en)2015-06-102016-12-15California Institute Of TechnologySepsis treatment and related compositions methods and systems
CA2997211A1 (en)2015-08-192017-02-23President And Fellows Of Harvard CollegeLipidated psa compositions and methods
JP6830105B2 (en)2015-09-292021-02-17クレッシェンド バイオサイエンス インコーポレイテッド Biomarkers and methods for assessing disease activity in psoriatic arthritis
WO2017058999A2 (en)2015-09-292017-04-06Crescendo BioscienceBiomarkers and methods for assessing response to inflammatory disease therapy withdrawal
EP3150716A1 (en)*2015-09-292017-04-05Institut PasteurImmunological signatures and parameters predicting therapeutic responses to anti-tnf therapy
US11285210B2 (en)2016-02-032022-03-29Outlook Therapeutics, Inc.Buffer formulations for enhanced antibody stability
WO2017151755A1 (en)*2016-03-022017-09-08Crescendo BioscienceBiomarkers and methods for predicting response to discontinuation of inflammatory disease therapy
EP3484441A4 (en)2016-07-152020-03-18President and Fellows of Harvard CollegeGlycolipid compositions and methods of use
JP2018070473A (en)*2016-10-262018-05-10エーザイ・アール・アンド・ディー・マネジメント株式会社Pharmaceutical composition for treating rheumatoid arthritis
MA47106A (en)2016-12-212019-10-30Amgen Inc ANTI-TNF ALPHA ANTIBODY FORMULATIONS
WO2019087200A1 (en)*2017-11-062019-05-09Rambam Med-Tech Ltd.Prognostic methods for anti-tnfa treatment
JP7514458B2 (en)*2018-12-072024-07-11株式会社Ｄｎａチップ研究所 Method for predicting efficacy of therapeutic drugs for rheumatoid arthritis and biomarkers used therein
KR102454358B1 (en)*2020-06-112022-10-14주식회사 미토스테라퓨틱스Composition for prevention or treatment of disease caused by muscle loss comprising expression inhibitors of PHF20
EP4232603A1 (en)*2020-10-202023-08-30Institut National de la Santé et de la Recherche Médicale (INSERM)Method for predicting the response to tnf inhibitors
WO2022264134A1 (en)*2021-06-132022-12-22Technion Research & Development Foundation LimitedMethod for determining suitability to anti-tnf alpha therapy
WO2025031446A1 (en)*2023-08-092025-02-13厦门大学Citrullinated setdb1 polypeptide and use thereof in diagnosis of rheumatoid arthritis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0154316B1 (en)1984-03-061989-09-13Takeda Chemical Industries, Ltd.Chemically modified lymphokine and production thereof
DE68925966T2 (en)1988-12-221996-08-29Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
CA2485553A1 (en)1989-09-051991-03-21Immunex CorporationTumor necrosis factor - .alpha. and - .beta. receptors
US5656272A (en)1991-03-181997-08-12New York University Medical CenterMethods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1994006476A1 (en)1992-09-151994-03-31Immunex CorporationMethod of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6090382A (en)1996-02-092000-07-18Basf AktiengesellschaftHuman antibodies that bind human TNFα
CN103275221B (en)1996-02-092016-08-17艾伯维生物技术有限公司People's antibody in conjunction with human TNF alpha
US6506607B1 (en)*1997-12-242003-01-14Millennium Pharmaceuticals, Inc.Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
US6607879B1 (en)1998-02-092003-08-19Incyte CorporationCompositions for the detection of blood cell and immunological response gene expression
SK1152003A3 (en)2000-06-292003-07-01Abbott LabDual specificity antibodies and methods of making and using
UA81743C2 (en)2000-08-072008-02-11Центокор, Инк.HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
BR0206160A (en)2001-05-252004-10-26Abbott Gmbh & Co Kg Use of anti-TNF antibodies as medicines in the treatment of septic disorders of anemic patients.
CA2385745C (en)2001-06-082015-02-17Abbott Laboratories (Bermuda) Ltd.Methods of administering anti-tnf.alpha. antibodies
US20030161828A1 (en)2002-02-192003-08-28Abbott Gmbh & Co. KgUse of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20030206898A1 (en)2002-04-262003-11-06Steven FischkoffUse of anti-TNFalpha antibodies and another drug
US20040009172A1 (en)2002-04-262004-01-15Steven FischkoffUse of anti-TNFalpha antibodies and another drug
PT1944322E (en)2002-07-192015-07-01Abbvie Biotechnology LtdTreatment of tnf alpha related disorders
US20090280065A1 (en)2006-04-102009-11-12Willian Mary KUses and Compositions for Treatment of Psoriasis
DE10234524A1 (en)*2002-07-242004-02-12Oligene GmbhArray of probes derived from monocyte-macrophage genes, useful e.g. for diagnosis, prognosis and therapeutic monitoring of rheumatoid arthritis and other inflammatory diseases
US20040033228A1 (en)2002-08-162004-02-19Hans-Juergen KrauseFormulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en)2002-10-242014-02-28Abbvie Biotechnology LtdLow dose methods for treating disorders in which tnf? activity is detrimental
JP4500683B2 (en)2002-11-012010-07-14バイエル・ヘルスケア・エルエルシー Macromolecule concentration method
US20040086532A1 (en)2002-11-052004-05-06Allergan, Inc.,Botulinum toxin formulations for oral administration
CA2555791A1 (en)2004-02-122005-08-25Merck Patent Gesellschaft Mit Beschraenkter HaftungHighly concentrated liquid formulations of anti-egfr antibodies
TWI439284B (en)2004-04-092014-06-01Abbvie Biotechnology LtdMultiple-variable dose regimen for treating tnfα-related disorders
WO2006041970A2 (en)2004-10-082006-04-20Abbott Biotechnology Ltd.Treatment of respiratory syncytial virus (rsv) infection
WO2007011390A2 (en)2004-10-092007-01-25Government Of The United States As Represented By The Secretary Of The ArmyLarge-scale production of human serum butyrylcholinesterase as a bioscavenger
US7541028B2 (en)2005-01-042009-06-02Gp Medical, Inc.Nanoparticles for monoclonal antibody delivery
FR2882763B1 (en)*2005-03-012007-05-18Biomerieux Sa METHOD FOR THE PROGNOSIS OF A RESPONSE TO A TREATMENT
WO2006113666A2 (en)2005-04-192006-10-26Massachusetts Institute Of TechnologyAmphiphilic polymers and methods of use thereof
BRPI0610058A2 (en)2005-05-162010-05-25Abbott Biotech Ltd use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en)2005-08-192007-02-22Hoffman Rebecca SMethod of treating depression using a TNF-alpha antibody
US7612181B2 (en)2005-08-192009-11-03Abbott LaboratoriesDual variable domain immunoglobulin and uses thereof
DK1948235T3 (en)2005-11-012013-11-25Abbvie Biotechnology Ltd Methods to determine the effectiveness of adalimumab in patients with Bechterew's disease with CTX-II and MMP3 as biomarkers
EP1795610A1 (en)*2005-12-062007-06-13Oligene GmbHA composition of nucleic acid sequences, specific for inflammatory disease, in particular rheumatoid arthritis
US20070202051A1 (en)2006-02-102007-08-30Pari GmbhAerosols for sinunasal drug delivery
KR20150064254A (en)2006-04-052015-06-10애브비 바이오테크놀로지 리미티드Antibody purification
US20080118496A1 (en)2006-04-102008-05-22Medich John RUses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120626A2 (en)2006-04-102007-10-25Abbott Biotechnology Ltd.Uses and compositions for treatment of ankylosing spondylitis
EP2010214A4 (en)2006-04-102010-06-16Abbott Biotech LtdUses and compositions for treatment of rheumatoid arthritis
EP2007426A4 (en)2006-04-102010-06-16Abbott Biotech LtdUses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en)2006-04-192008-06-05Medich John RUses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en)2006-06-082008-12-18Hoffman Rebecca SUses and compositions for treatment of psoriatic arthritis
KR101396797B1 (en)2006-06-302014-05-26애브비 바이오테크놀로지 리미티드Automatic injection device
WO2008028044A2 (en)2006-08-302008-03-06Centocor, Inc.Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
MX346523B (en)2006-09-132017-03-23Abbvie IncCell culture improvements.
CN104072612A (en)2006-10-272014-10-01艾伯维生物技术有限公司Crystalline anti-hTNFalpha antibodies
CN101848733A (en)2007-07-132010-09-29艾博特生物技术有限公司The method and composition that is used for pulmonary administration TNF alpha inhibitor
US8753839B2 (en)2007-08-082014-06-17Abbvie Inc.Compositions and methods for crystallizing antibodies

Cited By (90)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8906373B2 (en)2002-07-192014-12-09Abbvie Biotechnology Ltd.Use of TNF-alpha inhibitor for treatment of psoriasis
US9090689B1 (en)2002-07-192015-07-28Abbvie Biotechnology Ltd.Use of TNFα inhibitor for treatment of psoriasis
US8986693B1 (en)2004-04-092015-03-24Abbvie Biotechnology Ltd.Use of TNFα inhibitor for treatment of psoriasis
US9061005B2 (en)2004-04-092015-06-23Abbvie Biotechnology LtdMultiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9499615B2 (en)2004-04-092016-11-22Abbvie Biotechnology LtdMultiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9512216B2 (en)2004-04-092016-12-06Abbvie Biotechnology Ltd.Use of TNFα inhibitor
US8961973B2 (en)2004-04-092015-02-24Abbvie Biotechnology Ltd.Multiple-variable dose regimen for treating TNFα-related disorders
US8961974B2 (en)2004-04-092015-02-24Abbvie Biotechnology Ltd.Multiple-variable dose regimen for treating TNFα-related disorders
US9187559B2 (en)2004-04-092015-11-17Abbvie Biotechnology LtdMultiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US20060009385A1 (en)*2004-04-092006-01-12Abbott Biotechnology Ltd.Multiple-variable dose regimen for treating TNFalpha-related disorders
US8889136B2 (en)2004-04-092014-11-18Abbvie Biotechnology Ltd.Multiple-variable dose regimen for treating TNFα-related disorders
US9086418B2 (en)2005-11-012015-07-21Abbvie Biotechnology Ltd.Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US9913902B2 (en)2006-04-052018-03-13Abbvie Biotechnology Ltd.Purified antibody composition
US8895009B2 (en)2006-04-052014-11-25Abbvie Biotechnology Ltd.Purified antibody composition
US8906372B2 (en)2006-04-052014-12-09Abbvie Biotechnology Ltd.Purified antibody composition
US9096666B2 (en)2006-04-052015-08-04Abbvie Biotechnology LtdPurified antibody composition
US9273132B2 (en)2006-04-052016-03-01Abbvie Biotechnology LtdPurified antibody composition
US9102723B2 (en)2006-04-052015-08-11Abbvie Biotechnology LtdPurified antibody composition
US8916153B2 (en)2006-04-052014-12-23Abbvie Biotechnology Ltd.Purified antibody composition
US8883156B2 (en)2006-04-052014-11-11Abbvie Biotechnology Ltd.Purified antibody composition
US11083792B2 (en)2006-04-052021-08-10Abbvie Biotechnology LtdPurified antibody composition
US9328165B2 (en)2006-04-052016-05-03Abbvie Biotechnology Ltd.Purified antibody composition
US20080166348A1 (en)*2006-04-102008-07-10Hartmut KupperUses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en)2006-04-102017-03-28Abbvie Biotechnology LtdMethods and compositions for treatment of skin disorders
US9279015B2 (en)2006-04-102016-03-08Robert L. WongMethods for treatment of ankylosing spondylitis using TNF alpha antibodies
US9399061B2 (en)2006-04-102016-07-26Abbvie Biotechnology LtdMethods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8926975B2 (en)2006-06-082015-01-06Abbvie Biotechnology LtdMethod of treating ankylosing spondylitis
US20100021451A1 (en)*2006-06-082010-01-28Wong Robert LUses and compositions for treatment of ankylosing spondylitis
US8772458B2 (en)2006-10-272014-07-08Abbvie Biotechnology LtdCrystalline anti-hTNFalpha antibodies
US20090110679A1 (en)*2007-07-132009-04-30Luk-Chiu LiMethods and compositions for pulmonary administration of a TNFa inhibitor
US8753839B2 (en)2007-08-082014-06-17Abbvie Inc.Compositions and methods for crystallizing antibodies
US20090148513A1 (en)*2007-08-082009-06-11Wolfgang FraunhoferCompositions and methods for crystallizing antibodies
US9085619B2 (en)2007-11-302015-07-21Abbvie Biotechnology Ltd.Anti-TNF antibody formulations
US11167030B2 (en)2007-11-302021-11-09Abbvie Biotechnology LtdProtein formulations and methods of making same
US11191834B2 (en)2007-11-302021-12-07Abbvie Biotechnology LtdProtein formulations and methods of making same
US20100278822A1 (en)*2009-05-042010-11-04Abbott Biotechnology, Ltd.Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US8747854B2 (en)2010-06-032014-06-10Abbvie Biotechnology Ltd.Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
US9334320B2 (en)2010-06-032016-05-10Abbvie Biotechnology Ltd.Methods of treating moderate to severe hidradenitis suppurativa with anti-TNFalpha antibody
US9255143B2 (en)2011-04-272016-02-09Abbvie Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en)2011-04-272016-11-29Abbvie Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9090688B2 (en)2011-04-272015-07-28Abbvie Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9062106B2 (en)2011-04-272015-06-23Abbvie Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9365645B1 (en)2011-04-272016-06-14Abbvie, Inc.Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013138909A1 (en)*2012-03-192013-09-26University Of ManitobaDetection and modulation of rheumatoid arthritis
US9957318B2 (en)2012-04-202018-05-01Abbvie Inc.Protein purification methods to reduce acidic species
US9334319B2 (en)2012-04-202016-05-10Abbvie Inc.Low acidic species compositions
US9181572B2 (en)2012-04-202015-11-10Abbvie, Inc.Methods to modulate lysine variant distribution
US9505833B2 (en)2012-04-202016-11-29Abbvie Inc.Human antibodies that bind human TNF-alpha and methods of preparing the same
US9708400B2 (en)2012-04-202017-07-18Abbvie, Inc.Methods to modulate lysine variant distribution
US9683033B2 (en)2012-04-202017-06-20Abbvie, Inc.Cell culture methods to reduce acidic species
US9150645B2 (en)2012-04-202015-10-06Abbvie, Inc.Cell culture methods to reduce acidic species
US9193787B2 (en)2012-04-202015-11-24Abbvie Inc.Human antibodies that bind human TNF-alpha and methods of preparing the same
US9346879B2 (en)2012-04-202016-05-24Abbvie Inc.Protein purification methods to reduce acidic species
US9359434B2 (en)2012-04-202016-06-07Abbvie, Inc.Cell culture methods to reduce acidic species
US9249182B2 (en)2012-05-242016-02-02Abbvie, Inc.Purification of antibodies using hydrophobic interaction chromatography
US9234033B2 (en)2012-09-022016-01-12Abbvie, Inc.Methods to control protein heterogeneity
US9206390B2 (en)2012-09-022015-12-08Abbvie, Inc.Methods to control protein heterogeneity
US9512214B2 (en)2012-09-022016-12-06Abbvie, Inc.Methods to control protein heterogeneity
US9290568B2 (en)2012-09-022016-03-22Abbvie, Inc.Methods to control protein heterogeneity
US9067990B2 (en)2013-03-142015-06-30Abbvie, Inc.Protein purification using displacement chromatography
US9499614B2 (en)2013-03-142016-11-22Abbvie Inc.Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en)2013-03-142014-12-30Abbvie, Inc.Mutated anti-TNFα antibodies and methods of their use
US9708399B2 (en)2013-03-142017-07-18Abbvie, Inc.Protein purification using displacement chromatography
US9387246B2 (en)2013-09-032016-07-12L. Douglas GrahamTreatment methods for rheumatoid arthritis
US9598667B2 (en)2013-10-042017-03-21Abbvie Inc.Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9200069B2 (en)2013-10-182015-12-01Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9266949B2 (en)2013-10-182016-02-23Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9085618B2 (en)2013-10-182015-07-21Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)2013-10-182015-11-10Abbvie, Inc.Modulated lysine variant species compositions and methods for producing and using the same
US9688752B2 (en)2013-10-182017-06-27Abbvie Inc.Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9200070B2 (en)2013-10-182015-12-01Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9315574B2 (en)2013-10-182016-04-19Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9499616B2 (en)2013-10-182016-11-22Abbvie Inc.Modulated lysine variant species compositions and methods for producing and using the same
US9522953B2 (en)2013-10-182016-12-20Abbvie, Inc.Low acidic species compositions and methods for producing and using the same
US9017687B1 (en)2013-10-182015-04-28Abbvie, Inc.Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8946395B1 (en)2013-10-182015-02-03Abbvie Inc.Purification of proteins using hydrophobic interaction chromatography
US9550826B2 (en)2013-11-152017-01-24Abbvie Inc.Glycoengineered binding protein compositions
US10179811B2 (en)2015-04-102019-01-15Fresenius Kabi Deutschland GmbhMethods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody
US10689440B2 (en)2015-04-102020-06-23Fresenius Kabi Deutschland GmbhMethod of treating Crohn's disease and ulcerative colitis by using an induction dosing regimen of adalimumab
US10669333B2 (en)2015-04-102020-06-02Fresenius Kabi Deutschland GmbhMethod of treating a tumor necrosis factor α (TNFα)-related disorder by using an induction dosing regimen of adalimumab
JP2022101590A (en)*2016-01-292022-07-06ブループリント バイオ，インコーポレイテッドPrediction of therapeutic response in inflammatory conditions
JP2019511924A (en)*2016-01-292019-05-09ブループリント バイオ，インコーポレイテッド Predicting the therapeutic response of inflammatory conditions
US9845505B2 (en)2016-01-292017-12-19BluePrint Bio, Inc.Prediction of therapeutic response in inflammatory conditions
EP4163393A1 (en)*2016-01-292023-04-12Liquid Bioscience, Inc.Prediction of therapeutic response in inflammatory conditions
WO2017132557A3 (en)*2016-01-292017-09-14BluePrint Bio, Inc.Prediction of therapeutic response in inflammatory conditions
US11987620B2 (en)2018-03-162024-05-21Scipher Medicine CorporationMethods of treating a subject with an alternative to anti-TNF therapy
US11783913B2 (en)2019-06-272023-10-10Scipher Medicine CorporationMethods of treating a subject suffering from rheumatoid arthritis with alternative to anti-TNF therapy based in part on a trained machine learning classifier
US12062415B2 (en)2019-06-272024-08-13Scipher Medicine CorporationMethods of treating a subject suffering from rheumatoid arthritis with anti-TNF therapy based in part on a trained machine learning classifier
GB2616129A (en)*2020-09-012023-08-30Scipher Medicine CorpMethods and systems for predicting response to anti-TNF therapies
WO2022051245A3 (en)*2020-09-012022-04-14Scipher Medicine CorporationMethods and systems for predicting response to anti-tnf therapies

Also Published As

Publication numberPublication date
US8092998B2 (en)2012-01-10
EP2165194A2 (en)2010-03-24
EP2165194A4 (en)2010-09-08
WO2008150491A2 (en)2008-12-11
US20090017472A1 (en)2009-01-15
EP2679996A1 (en)2014-01-01
EP2679995A1 (en)2014-01-01
WO2008150491A3 (en)2009-02-05

Similar Documents

PublicationPublication DateTitle
US8092998B2 (en)Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
Landolt-Marticorena et al.Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus
Yao et al.Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus
US11795496B2 (en)Epigenetic chromosome interactions
CA2889087C (en)Diagnostic method for predicting response to tnf.alpha. inhibitor
US11262358B2 (en)Infiltrating immune cell proportions predict anti-TNF response in colon biopsies
US20130095099A1 (en)Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)
KR20160052585A (en)SYSTEMS, DEVICES AND METHODS FOR ANTI-TLlA THERAPY
AU2016210996A1 (en)Therapeutic target and biomarker in IBD
Devauchelle‐Pensec et al.Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab
EP2527473A2 (en)B cell signature associated with tolerance in transplant recipients
WO2016179469A1 (en)Methods and compositions for diagnosing and treating inflammatory bowel disease
WO2012101183A2 (en)Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
WO2015132241A1 (en)Treatment of inflammatory diseases
CA3030165A1 (en)Biomarkers for detection and treatment of mast cell activity-associated disorders
EP4162042A1 (en)Markers and cellular antecedents of rheumatoid arthritis flares
KR101620274B1 (en)Composition for diagnosis of obesity and uses thereof
HK1193465A (en)Biomarkers predictive of the responsiveness to tnf-alfa inhibitors in autoimmune disorders
US20220351806A1 (en)Biomarker Panels for Guiding Dysregulated Host Response Therapy
HK1193466A (en)Biomarkers predictive of the responsiveness to tnf-alfa inhibitors in autoimmune disorders
US20150369823A1 (en)Method to identify patients that will likely respond to anti-tnf therapy
US20160251716A1 (en)Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
SutcliffeExploring the Influence of Treatment on CD4+ T-Cell Sub-Populations in Patients Receiving Biologic Drugs for Their Inflammatory Arthritis
US20110200600A1 (en)Diagnosis and prognosis of immune disorders using stat4 expression
US20190249256A1 (en)Method for determining the risk of developing arthritis

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:ABBVIE INC., ILLINOIS

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030235/0856

Effective date:20120801

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
[8]ページ先頭
©2009-2025 Movatter.jp